1606150-08-6
Chemical Structure
BMS-986144
- CAS No.: 1606150-08-6
- Formula:C40H48D3F4N5O9S
- Molecular Weight:856.94
IUPAC Name: 1,1,1-trifluoro-2-methylpropan-2-yl ((2R,6S,7R,9R,13aS,14aR,16aS,Z)-7-ethyl-2-((7-fluoro-6-(methoxy-d3)isoquinolin-1-yl)oxy)-9-methyl-14a-(((1-methylcyclopropyl)sulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)carbamate
InChIKey: IJNUZTYJYYUXSD-YTEVSDLFSA-N
SMILES: O=C([C@H]1N2C[C@@H](C1)OC3=NC=CC4=C3C=C(C(OC([2H])([2H])[2H])=C4)F)N[C@@]5(C[C@H]5/C=C\CC[C@H](C[C@H]([C@@H](C2=O)NC(OC(C)(C(F)(F)F)C)=O)CC)C)C(NS(C6(CC6)C)(=O)=O)=O
Biological Activity: BMS-986144 is an orally active inhibitor of HCV NS3/4A protease. BMS-986144 binds to the active site of HCV NS3/4A protease and induces conformational changes in the protease. BMS-986144 reduces time-dependent CYP3A4 inhibition, exhibits hepatic microsomal metabolic stability, and undergoes oxidation of the macrocyclic linker chain. BMS-986144 can be used in studies related to hepatitis C virus infection[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BMS-986144 | BMS-986144 is an orally active inhibitor of HCV NS3/4A protease. BMS-986144 binds to the active site of HCV NS3/4A protease and induces conformational changes in the protease. BMS-986144 reduces time-dependent CYP3A4 inhibition, exhibits hepatic microsomal metabolic stability, and undergoes oxidation of the macrocyclic linker chain. BMS-986144 can be used in studies related to hepatitis C virus infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-986144 (non-deuterated) | BMS-986144 non-deuterated is the non-tritium form of BMS-986144 (HY-131905S). BMS-986144 non-deuterated is an orally active inhibitor of HCV NS3/4A protease. BMS-986144 non-deuterated binds to the active site of HCV NS3/4A protease and induces conformational changes in the protease. BMS-986144 non-deuterated reduces time-dependent CYP3A4 inhibition, exhibits hepatic microsomal metabolic stability, and undergoes oxidation of the macrocyclic linker chain. BMS-986144 non-deuterated can be used in studies related to hepatitis C virus infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
